Biology of Blood and Marrow Transplantation
Volume 12, Issue 12 , Pages 1310-1317 , December 2006

Long-Term Outcomes of Myeloablation and Autologous Transplantation of Relapsed Acute Myeloid Leukemia in Second Remission: A British Society of Blood and Marrow Transplantation Registry Study

  • Andrew D. Chantry

      Affiliations

    • Academic Unit of Bone Biology, University of Sheffield Medical School, Sheffield, UK
    • Corresponding Author InformationCorrespondence and reprint requests: Dr. Andrew Chantry, University of Sheffield Medical School, Academic Unit of Bone Biology, Beech Hill Road, Sheffield S10 2RX, United Kingdom.
    • ,
  • John A. Snowden

      Affiliations

    • Department of Haematology, Royal Hallamshire Hospital, Sheffield, UK
    • ,
  • Charles Craddock

      Affiliations

    • Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK
    • ,
  • Karl Peggs

      Affiliations

    • Department of Haematology, University College London Hospitals, London, UK
    • ,
  • Claire Roddie

      Affiliations

    • Department of Haematology, Hemel Hempstead General Hospital, Hemel Hempstead, UK
    • ,
  • Jenny I.O. Craig

      Affiliations

    • Department of Haematology, Addenbrooke’s Hospital, Cambridge, UK
    • ,
  • Kim Orchard

      Affiliations

    • Southampton University Hospitals Trust, Southampton, UK
    • ,
  • Keiren E. Towlson

      Affiliations

    • BSBMT Data Registry, University College Hospital, London, UK
    • ,
  • Rachel M. Pearce

      Affiliations

    • BSBMT Registry Cloudswood, Derbyshire, UK
    • ,
  • David I. Marks

      Affiliations

    • Adult BMT Unit, Bristol Children’s Hospital, Bristol, UK

Received 14 June 2006 ,Accepted 31 July 2006.

References 

  1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Eng J Med. 1999;341:1051–1062
  2. Burnett AK. Acute myeloid leukemia: treatment of adults under 60 years. Rev Clin Exp Hematol. 2002;6:26–45
  3. Leopold LH, Willemze R. The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature. Leukemia Lymphoma. 2002;43:715–727
  4. Brenner MK, Rill DR, Moen RC, et al. Gene-marking to trace relapse after autologous bone marrow transplantation. Lancet. 1993;341:85–86
  5. Meloni G, Vignetti M, Avvisati G, et al. BAVC regimen and autograft for acute myelogenous leukaemia in second complete remission. Bone Marrow Transplant. 1996;18:693–698
  6. Tomas F, Gomez-Garcia de Soria V, Lopez-Lorenzo JL, et al. Autologous or allogeneic bone marrow transplantation for acute myeloblastic leukemia in second complete remission: importance of duration of first complete remission in final outcome. Bone Marrow Transplant. 1996;17:979–984
  7. Gorin NC, Aegerter P, Auvert B, et al. Autologous bone marrow transplantation for AML in first remission: a European survey of the role of marrow purging. Blood. 1990;75:1606–1614
  8. Gorin NC, Labopin M, Fouillard L, et al. Retrospective evaluation of autologous bone marrow transplantation versus allogeneic bone marrow transplantation from an HLA-identical related donor in acute myelocytic leukaemia (A study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT)). Bone Marrow Transplant. 1996;18:111–117
  9. Lazarus HM, Perez WS, Klein JP, et al. Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. Br J Haematol. 2006;132:755–769
  10. Meloni G, Diverio D, Vignetti M, et al. Autologous bone marrow transplantation for acute promyelocytic leukaemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by polymerase chain reaction of the PML/RAR alpha fusion gene. Blood. 1997;90:1321–1325
  11. Lo Coco F, Diverio D, Avvisati G, et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood. 1999;94:2225–2229
  12. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 Trial. Blood. 1998;92:2322–2333
  13. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2005;
  14. Therneau T, Lumley T. Survival: Survival analysis, including penalized likelihood. R package, version 2.18. Vienna, Austria: R Foundation for Statistical Computing; 2005;
  15. Gray B. cmprsk: subdistribution analysis of competing risks. R package, version 2.15. Vienna, Austria: R Foundation for Statistical Computing; 2004;
  16. Linker CA, Damon LE, Ries CA, et al. Autologous stem cell transplantation for advanced AML. Bone Marrow Transplant. 2002;29:297–301
  17. Craddock C, Tauro S, Moss P, et al. Biology and management of relapsed acute myeloid leukaemia. Br J Haematol. 2005;129:18–34
  18. Sierra J, Storer B, Hansen JA, et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant. 2000;26:397–404
  19. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756–763
  20. Martino R, Caballero MD, Perez Simon JA, et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood. 2002;100:2243–2245
  21. Sayer HG, Kroger M, Beyer J, et al. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant. 2003;31:1089–1095
  22. Taussig DC, Davies AJ, Cavenagh JD, et al. Durable remissions of myelodysplastic syndrome and acute myeloid leukaemia after reduced-intensity allografting. J Clin Oncol. 2003;21:3060–3065
  23. Wong R, Giralt SA, Martin T, et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment of myeloid malignancies in patients older than 55 years of age. Blood. 2003;102:3052–3059
  24. Ho AYL, Pagliuca A, Kenyon M, et al. Reduced-intensity allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukaemia with multilineage dysplasia using fludarabine, busulphan and alemtuzumab (FBC) conditioning. Blood. 2004;104:1616–1623
  25. Tauro S, Craddock C, Peggs K, et al. Allogeneic stem cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukaemia and myelodysplasia. J Clin Oncol. 2006;23:9387–9393
  26. Yeager AM, Kaizer H, Santos GW, et al. Autologous bone marrow transplantation in patients with acute nonlymphoblastic leukaemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med. 1986;315:141–147
  27. Rowley SD, Lohen M, Radich J, et al. Isolation of CD34+ cells from blood stem cell components using the Baxter Isolex system. Bone Marrow Transplant. 1998;21:1253–1262
  28. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003;102:3447–3454

 Supported by the Leukaemia Research Fund (grant 03/100, to D.M.).

PII: S1083-8791(06)00521-0

doi: 10.1016/j.bbmt.2006.07.015

Biology of Blood and Marrow Transplantation
Volume 12, Issue 12 , Pages 1310-1317 , December 2006

Article Tools

* Image Usage & Resolution